Enzo Biochem (NYSE:ENZ) Now Covered by Analysts at StockNews.com

Stock analysts at StockNews.com began coverage on shares of Enzo Biochem (NYSE:ENZ) in a research note issued on Monday. The firm set a “hold” rating on the medical research company’s stock.

Enzo Biochem Trading Up 1.8 %

Shares of NYSE ENZ opened at $1.14 on Monday. The business’s fifty day simple moving average is $1.12 and its 200-day simple moving average is $1.12. Enzo Biochem has a 12-month low of $0.99 and a 12-month high of $1.50.

Institutional Investors Weigh In On Enzo Biochem

An institutional investor recently raised its position in Enzo Biochem stock. XTX Topco Ltd increased its holdings in shares of Enzo Biochem, Inc. (NYSE:ENZ) by 94.5% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 28,262 shares of the medical research company’s stock after purchasing an additional 13,735 shares during the quarter. XTX Topco Ltd owned approximately 0.05% of Enzo Biochem worth $31,000 at the end of the most recent quarter. 36.90% of the stock is currently owned by hedge funds and other institutional investors.

Enzo Biochem Company Profile

Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.